Skip to main
VSTM
VSTM logo

Verastem (VSTM) Stock Forecast & Price Target

Verastem (VSTM) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 59%
Buy 35%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Verastem Inc. is advancing its late-stage pipeline with promising data from the FRAME and RAMP 201 trials, suggesting that its combination therapy of avutometinib and defactinib may offer significant efficacy and improved safety advantages, particularly for KRAS mutant cancers. The projected global sales potential of over $400 million for low-grade serous ovarian carcinoma (LGSOC) and $200 million for non-small cell lung cancer (NSCLC) starting as early as mid-2025 indicates a robust opportunity for revenue generation. Moreover, recent communications with management have resulted in heightened confidence in the company's trajectory, supported by a focus on effective therapeutic outcomes and the potential for the upcoming clinical milestones to drive share appreciation.

Bears say

Verastem Inc. faces significant challenges that contribute to a negative outlook on its stock, primarily due to the lack of substantial randomized data for its lead drug, avutometinib, raising concerns about its efficacy and safety in upcoming clinical trials. Competitive pressures could hinder patient enrollment and reduce market uptake, while the company's targeted approach may limit its market potential given the small addressable population. Additionally, if the clinical development fails to yield positive results, Verastem's stock could decline sharply, potentially trading near its net cash position with minimal value attributed to its pipeline.

Verastem (VSTM) has been analyzed by 17 analysts, with a consensus rating of Buy. 59% of analysts recommend a Strong Buy, 35% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Verastem (VSTM) Forecast

Analysts have given Verastem (VSTM) a Buy based on their latest research and market trends.

According to 17 analysts, Verastem (VSTM) has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Verastem (VSTM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.